Junshi Biosciences (688180.SH): Phase III clinical study of anti-IL-17A monoclonal antibody for the treatment of severe plaque psoriasis reaches primary endpoint.

Zhtng cijng APP xn, Jn sh shngw (688180.SH) gnggo, gngs chnpn chngz rnyun hu kng IL-17A dn kzhn kngt (diho: JS005) zi zhlio zhng zhngd bn kui zhung ynp bng de yxing du zhngxn, suj, shung mng, pngxng, nwi j duzho de gunjin zhcxng q lnchung ynji (ynji binho: JS005-005-III-PsO) zhng qd yngxng jigu, gngtng zhyo ynji zhngdin h gunjin cyo zhngdin jn jyu tngj xu xinzhng xng h lnchung yy de gishn. Gngs jhu jing y jnj xing jingun bmn dt jio sh gi chnpn de shngsh xk shnqng.